Incyte Biosciences Distribution B.V.
8 products tracked · names used in filings: Incyte Biosciences Distribution B.V.
Upcoming milestones
Mon 23 Nov 2026🇪🇺 Expected EC decisionestimatein 9 days
Povofortay (povorcitinib): expected EC decision
Estimated as CHMP opinion (2026-09-17) + 67 days, the standard Commission decision period. Not an official date. · Incyte Biosciences Distribution B.V. · source
Recent milestones
Thu 17 Sep 2026🇪🇺 CHMP positive opinion
Povofortay (povorcitinib): CHMP positive opinion
Products
| Product | Status | Approved | |
|---|---|---|---|
| 🇪🇺 | Parsaclisib Incyte Biosciences Distribution B.V. parsaclisib | Application withdrawn | |
| 🇪🇺 | Povofortay povorcitinib | Opinion | |
| 🇪🇺 | Zynyz retifanlimab | Application withdrawn | |
| 🇪🇺 | Zynyz retifanlimab | Authorised | 2024-04-19 |
| 🇪🇺 | Opzelura ruxolitinib | Authorised | 2023-04-19 |
| 🇪🇺 | Minjuvi tafasitamab | Authorised | 2021-08-26 |
| 🇪🇺 | Pemazyre pemigatinib | Authorised | 2021-03-26 |
| 🇪🇺 | Iclusig ponatinib | Authorised | 2013-07-01 |
Information from official EMA, FDA, Federal Register and SEC records. Dates marked company-announced come from the company's own SEC filing; dates marked estimate are calculated, not official. Not investment or medical advice; always confirm on the source.